Ottawa, March 8, 2021 – Innovative Medicines Canada (IMC) issued the following statement about treatment options for COVID-19 patients.
“Since the pandemic began, there has been unprecedented collaboration across governments, academia, the private and philanthropic sectors to discover, develop and deliver treatments for COVID-19.
“The innovative pharmaceutical industry has also been working with federal and provincial governments to ensure that Canadian COVID-19 patients have access to as many treatment options as possible. IMC strongly believes that working together with partners across all sectors will allow us to come out of this pandemic faster by limiting the burden it has caused to health care systems across the country.
“Several COVID-19 therapeutics have been approved/authorized by Health Canada, the European Medicines Agency, the U.S. Food and Drug Administration and other international regulators, and should remain treatment options for Canadians.
“IMC is advocating that all Canadian jurisdictions work together to ensure approved and authorized medicines are accessible to all Canadians affected by COVID-19.”
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
– 30 –
For further information:
Sarah Dion-Marquis
Director, Media and Public Relations
Telephone: 613-769-6510
E-mail: sdmarquis@imc-mnc.ca
